Dougan Lab Publications
Click below to see a up-to-date listing. Inhibition of CDK4/6 promotes CD8 T-cell memory formation.
Heckler M*, Ali LR*, Clancy-Thompson E, Qiang L, Ventre KS, Lenehan P, Roehle K, Luoma A, Boelaars K, Peters V, McCreary J, Boschert T, Wang ES, Suo S, Marangoni F, Mempel TR, Long HW, Wucherpfennig KW, Dougan M, Gray NS, Yuan GC, Goel S, Tolaney SM, Dougan SK. Cancer Discov. 2021 May 3 epub ahead of print. Transnuclear mice reveal Peyer's patch iNKT cells that regulate B-cell class switching to IgG1. Clancy-Thompson E, Chen GZ, LaMarche NM, Ali LR, Jeong HJ, Crowley SJ, Boelaars K, Brenner MB, Lynch L, Dougan SK. EMBO J. 2019 May 31. Altered Binding of Tumor Antigenic Peptides to MHC Class I Affects CD8+ T Cell-Effector Responses. Clancy-Thompson E, Devlin CA, Tyler PM, Servos MM, Ali LR, Ventre KS, Bhuiyan MA, Bruck PT, Birnbaum ME, Dougan SK. Cancer Immunol Res. 2018 Dec;6(12):1524-1536. Radiation and Local Anti-CD40 Generate an Effective in situ Vaccine in Preclinical Models of Pancreatic Cancer. Yasmin-Karim S, Bruck PT, Moreau M, Kunjachan S, Chen GZ, Kumar R, Grabow S, Dougan SK*, Ngwa W*. Front Immunol. 2018 Sep 7;9:2030. Rapid CLIP dissociation from MHC II promotes an unusual antigen presentation pathway in autoimmunity. Ito Y, Ashenberg O, Pyrdol J, Luoma AM, Rozenblatt-Rosen O, Hofree M, Christian E, Ferrari de Andrade L, Tay RE, Teyton L, Regev A, Dougan SK, Wucherpfennig KW. J Exp Med. 2018 Oct 1;215(10):2617-2635. Regulation of innate and adaptive antitumor immunity by IAP antagonists. Dougan SK, Dougan M. Immunotherapy. 2018 May 29. Unmasking Pancreatic Cancer: Epitope Spreading After Single Antigen Chimeric Antigen Receptor T-Cell Therapy in a Human Phase I Trial. Heckler M, Dougan SK. Gastroenterology. 2018 Jun 6. The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy. Krall JA, Reinhardt F, Mercury OA, Pattabiraman DR, Brooks MW, Dougan M, Lambert AW, Bierie B, Ploegh HL, Dougan SK, Weinberg RA. Sci Transl Med. 2018 Apr 11;10(436). Anti-CTLA-4 therapy requires an Fc domain for efficacy. Ingram JR, Blomberg OS, Rashidian M, Ali L, Garforth S, Fedorov E, Fedorov AA, Bonanno JB, Le Gall C, Crowley S, Espinosa C, Biary T, Keliher EJ, Weissleder R, Almo SC, Dougan SK, Ploegh HL, Dougan M. Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):3912-3917. Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1-Specific VHHs. Dougan M, Ingram JR, Jeong HJ, Mosaheb MM, Bruck PT, Ali L, Pishesha N, Blomberg O, Tyler PM, Servos MM, Rashidian M, Nguyen QD, von Andrian UH, Ploegh HL, Dougan SK. Cancer Immunol Res. 2018 Apr;6(4):389-401. Generation of Ca2+-independent sortase A mutants with enhanced activity for protein and cell surface labeling. Jeong HJ, Abhiraman GC, Story CM, Ingram JR, Dougan SK. PLoS One. 2017 Dec 4;12(12):e0189068. IAP antagonists enhance cytokine production from mouse and human iNKT cells. Clancy-Thompson E, Ali L, Bruck PT, Exley MA, Blumberg RS, Dranoff G, Dougan M, Dougan SK. Cancer Immunol Res. 2018 Jan;6(1):25-35. PD-L1 is an activation-independent marker of brown adipocytes. Ingram JR, Dougan M, Rashidian M, Knoll M, Keliher EJ, Garrett S, Garforth S, Blomberg OS, Espinosa C, Bhan A, Almo SC, Weissleder R, Lodish H, Dougan SK, Ploegh HL. Nat Commun. 2017 Sep 21;8(1):647. Monoclonal Invariant NKT (iNKT) Cell Mice Reveal a Role for Both Tissue of Origin and the TCR in Development of iNKT Functional Subsets. Clancy-Thompson E, Chen GZ, Tyler PM, Servos MM, Barisa M, Brennan PJ, Ploegh HL*, Dougan SK*. J Immunol. 2017 Jun 2. Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy. Tyler PM, Servos MM, de Vries RC, Klebanov B, Kashyap T, Sacham S, Landesman Y, Dougan M, Dougan SK. Mol Cancer Ther. 2017 Mar;16(3):428-439. Tissue-specific emergence of regulatory and intraepithelial T cells from a clonal T cell precursor. Bilate AM, Bousbaine D, Mesin L, Agudelo M, Leube J, Kratzert A, Dougan SK, Victora GD, Ploegh HL. Sci Immunol. 2016 Aug 26;1(2) Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity. Dougan SK, Dougan M, Kim J, Turner JA, Ogata S, Cho HI, Jaenisch R, Celis E, Ploegh HL. Cancer Immunol Res. 2013 Aug;1(2):99-111. doi: 10.1158/2326-6066.CIR-13-0047. Antigen-specific B-cell receptor sensitizes B cells to infection by influenza virus. Dougan SK, Ashour J, Karssemeijer RA, Popp MW, Avalos AM, Barisa M, Altenburg AF, Ingram JR, Cragnolini JJ, Guo C, Alt FW, Jaenisch R, Ploegh HL. Nature. 2013 Nov 21;503(7476):406-9. doi: 10.1038/nature12637. Epub 2013 Oct 20. In vivo discovery of immunotherapy targets in the tumour microenvironment. Zhou P, Shaffer DR, Alvarez Arias DA, Nakazaki Y, Pos W, Torres AJ, Cremasco V, Dougan SK, Cowley GS, Elpek K, Brogdon J, Lamb J, Turley SJ, Ploegh HL, Root DE, Love JC, Dranoff G, Hacohen N, Cantor H, Wucherpfennig KW. Nature. 2014 Feb 6;506(7486):52-7. doi: 10.1038/nature12988. Epub 2014 Jan 29. IgG1+ ovalbumin-specific B-cell transnuclear mice show class switch recombination in rare allelically included B cells. Dougan SK, Ogata S, Hu CC, Grotenbreg GM, Guillen E, Jaenisch R, Ploegh HL. Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13739-44. doi: 10.1073/pnas.1210273109. Epub 2012 Aug 6. IAP inhibitors enhance co-stimulation to promote tumor immunity. Dougan M, Dougan S, Slisz J, Firestone B, Vanneman M, Draganov D, Goyal G, Li W, Neuberg D, Blumberg R, Hacohen N, Porter D, Zawel L, Dranoff G. J Exp Med. 2010 Sep 27;207(10):2195-206. doi: 10.1084/jem.20101123. Epub 2010 Sep 13. |
"Cancer Immunotherapy: Beyond Checkpoint Blockade" Annual Review article is published!
Dougan lab contributes to Immunity's 25th Anniversary edition with "GM-CSF, IL-3, and IL-5 Family of Cytokines: Regulators of Inflammation""Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities."
|